Apellis Pharmaceuticals Inc (NAS:APLS)
$ 39.68 -3.92 (-8.99%) Market Cap: 4.82 Bil Enterprise Value: 5.07 Bil PE Ratio: 0 PB Ratio: 18.04 GF Score: 38/100

Apellis Pharmaceuticals Inc SYFOVRE FDA Approval Call Transcript

Feb 17, 2023 / 09:30PM GMT
Release Date Price: $55.49 (+6.90%)
Operator

Thank you for standing by, and welcome to the Apellis SYFOVRE FDA approval conference call. (Operator Instructions) As a reminder, today's conference is being recorded.

I would now like to hand the conference over to your host, Meredith Kaya. Please begin.

Meredith Kaya
Apellis Pharmaceuticals, Inc. - SVP, IR & Strategic Finance

Thank you for joining us today to discuss the FDA approval of intravitreal pegcetacoplan, now with the brand name SYFOVRE, as the first and only treatment for geographic atrophy, or GA.

With me on the call are Co-Founder and Chief Executive Officer, Dr. Cedric Francois; Chief Medical Officer, Dr. Caroline Baumal; and Chief Commercial Officer, Adam Townsend. Tim Sullivan, Chief Financial Officer, will be available for the Q&A.

Before we begin, I would like to point out that we'll be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot